risankizumab · Skyrizi

Monoclonal antibody

Also known as BI 655066, ABBV-066

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: moderately to severely active CD or UC who have had an inadequate response to, lost response to, or...), Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (10)
EU
  • Moderately to severely active ulcerative colitis in adultspmlive.com
  • Moderately to severely active Crohn's disease in adultsnews.abbvie.com
  • Moderate to severe plaque psoriasis in adults (initial EU authorisation; PsA, Crohn's disease and ulcerative colitis added later)EMA
Product first approved 2019
JP
  • Moderately to severely active ulcerative colitis, induction and maintenance, where existing therapy is inadequatekyodonewsprwire.jp
  • Moderately to severely active Crohn's disease (IV 600 mg and SC 360 mg autodoser) where existing therapy is inadequatekyodonewsprwire.jp
  • Plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults with inadequate response to conventional therapies (first approval worldwide)antibodysociety.org
Product first approved 2019
KR
  • Moderately to severely active Crohn's disease in adults
Product first approved 2023pearceip.law
UK
  • Moderately to severely active Crohn's disease and ulcerative colitis
Product first approved 2022medicines.org.uk
CA
  • Moderately to severely active Crohn's disease (authorised in Canada since October 2022, per Health Canada)
  • Active psoriatic arthritis in adults (authorised in Canada since March 2022, per Health Canada)
Product first approved 2022dhpp.hpfb-dgpsa.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (31)
Crohn's Disease
NCT07499232 · Janssen Research & Development, LLC
2026-04-21 – 2030-12-11 · Crohn Disease
What this study did
Psoriasis
NCT03219437 · AbbVie
2018-07-30 – 2021-11-26 · Psoriasis
What this study did
NCT03478787 · AbbVie
2018-05-08 – 2020-07-08 · Psoriasis
What this study did
NCT03518047 · AbbVie
2018-07-19 – 2020-02-11 · Psoriasis
What this study did
Psoriatic Arthritis
Ulcerative Colitis
NCT07071519 · AbbVie
2025-07-28 – 2034-07 · Ulcerative Colitis
What this study did
NCT07177118 · First Affiliated Hospital of Wenzhou Medical University
2025-10-20 – 2028-10-20 · Crohn Disease, Crohn Disease and Ulcerative Colitis
What this study did
Other / comorbidity
Phase 2/3 (1)
Phase 2 (17)
Crohn's Disease
NCT06548542 · AbbVie
2024-09-04 – 2030-01 · Crohn's Disease
What this study did
NCT02513459 · AbbVie
2015-09-16 – 2019-06-19 · Crohn Disease
What this study did
Psoriasis
NCT05283135 · Oregon Medical Research Center
2022-03-01 – 2024-07-10 · Psoriasis
What this study did
NCT03000075 · AbbVie
2016-12-02 – 2018-06-20 · Psoriasis
What this study did
NCT02054481 · Boehringer Ingelheim
2014-02 – 2015-07 · Psoriasis
What this study did
Psoriatic Arthritis
NCT06865105 · AbbVie
2025-04-11 – 2029-08 · Psoriatic Arthritis
What this study did
NCT02986373 · AbbVie
2016-12-15 – 2018-07-30 · Psoriatic Arthritis
What this study did
NCT02719171 · AbbVie
2016-04 – 2017-08 · Arthritis, Psoriatic
What this study did
Ulcerative Colitis
NCT07697456 · AbbVie
2026-07-31 – 2031-10 · Crohn's Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT04583956 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-10-23 – 2021-09-13 · COVID-19
What this study did
NCT03926169 · AbbVie
2019-06-03 – 2021-08-02 · Hidradenitis Suppurativa
What this study did
NCT02443298 · AbbVie
2015-06-23 – 2018-02-02 · Asthma
What this study did
NCT02047110 · AbbVie
2014-01-28 – 2016-07-25 · Ankylosing Spondylitis (AS)
What this study did
Phase 1/2 (2)
Ulcerative Colitis
NCT07258641 · University Medical Center Groningen
2026-01-15 – 2028-04-01 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
NCT06606808 · University Medical Center Groningen
2024-11-08 – 2025-12 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
Phase 1 (19)
Psoriasis
NCT01577550 · AbbVie
2012-04 – 2014-05 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05083078 · Janssen Research & Development, LLC
2021-11-04 – 2022-07-01 · Arthritis, Psoriatic, Healthy
What this study did
Ulcerative Colitis
Other / comorbidity
NCT07466550 · AbbVie
2026-06-04 – 2027-01 · Healthy Volunteer
What this study did
NCT06487572 · AbbVie
2024-07-23 – 2025-02-07 · Healthy Volunteers
What this study did
NCT06054425 · AbbVie
2023-11-20 – 2024-05-06 · Healthy Volunteers
What this study did
NCT05567029 · AbbVie
2022-09-28 – 2023-04-20 · Healthy Volunteers
What this study did
NCT05274100 · AbbVie
2020-09-01 – 2021-07-06 · Healthy Volunteers
What this study did
NCT05268068 · AbbVie
2019-06-27 – 2020-04-26 · Healthy Volunteers
What this study did
NCT05283681 · AbbVie
2019-04-02 – 2019-11-11 · Healthy Volunteers
What this study did
NCT05305222 · AbbVie
2017-10-23 – 2018-06-15 · Healthy Volunteers
What this study did
NCT05283694 · AbbVie
2017-09-11 – 2018-06-12 · Healthy Volunteers
What this study did
Phase 4 (10)
Crohn's Disease
NCT07872449 · Yuki Horio
2026-10-01 – 2029-03-31 · Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT04630652 · Jaehwan Kim
2021-04-07 – 2025-05-13 · Psoriasis
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
NCT05685940 · University Hospital, Ghent
2020-04-05 – 2024-12-31 · Psoriasis Vulgaris
What this study did
NCT04722640 · Istituto Clinico Humanitas
2021-01-25 – 2022-01-31 · Psoriasis
What this study did
Ulcerative Colitis
NCT06346288 · AbbVie
2024-04-24 – 2026-02-05 · Inflammatory Bowel Disease
What this study did
Early phase / not applicable (1)
Crohn's Disease
NCT06298188 · Shaare Zedek Medical Center
2024-10-31 – 2026-10 · Crohn Disease
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Psoriatic Arthritis
NCT06641089 · MoonLake Immunotherapeutics AG
2024-10-15 – 2027-09-13 · Arthritis, Psoriatic
What this study did
NCT06624228 · UCB Biopharma SRL
2024-10-21 – 2026-06-03 · Psoriatic Arthritis
What this study did
Phase 1 (1)
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Psoriasis
NCT07933536 · AbbVie
2026-12-03 – 2028-12 · Moderate to Severe Psoriasis
What this study did
Phase 4 (1)
Crohn's Disease
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Psoriasis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risankizumab (Skyrizi): this drugApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02672852: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001
NCT02684370: PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00195676: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed)
NCT00237887: REVEAL: PASI 75 response rates of 71% after 16 weeks and 70% after 24 weeks of treatment with adalimumab 40 mg every other week.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT03701763: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5%
NCT03777436: Percentage of Participants With a Modified sPGA-G Response at Week 16 (Baseline and Week 16 of the Placebo-controlled Phase): Placebo-controlled Phase: Apremilast 30 mg 39.6% (95% CI 31.2 to 48) vs Placebo-controlled Phase: Placebo 19.5% (95% CI 12.7 to 26.3)
Betamethasone Dipropionate Emollient Spray (Sernivo)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03412747: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2%
NCT03370133: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7%
Brodalumab (Siliq)ApprovedMonoclonal antibodyIL-17 receptor APartial signal
NCT02982005: Coprimary endpoints at week 12: PASI 75 and sPGA success achieved by 92.5% (brodalumab 210mg Q2W) vs 0% (placebo), significantly higher
Calcipotriene / Betamethasone Dipropionate Cream (Wynzora)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptorPartial signal
NCT03802344: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9)
NCT03308799: PGA treatment success at week 8: 37.4% with CAL/BDP cream (MC2-01) vs 22.8% with CAL/BDP topical suspension (P<0.0001) and 3.7% with vehicle (P<0.0001) (Stein Gold et al., J Drugs Dermatol 2021).
Calcipotriene / Betamethasone Dipropionate Foam (Enstilar)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Calcipotriol / Betamethasone Dipropionate Gel (Taclonex)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaReliable signal
NCT02326298: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo).
NCT02326272: PASI 75 at Week 16 (CIMPASI-2): certolizumab pegol 200mg Q2W 81.4%, 400mg Q2W 82.6%, placebo 11.6% (P<0.0001 for both doses vs placebo).
Desoximetasone (Topicort Spray)ApprovedSmall moleculeGlucocorticoid receptor agonistPartial signal
NCT02618759: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (28 Days): DSXS1505 10/60 (16.7%) vs Placebo 3/59 (5.1%) missed phase 3 result · pivotal pending
NCT02932462: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis (from baseline to study day 29): DSXS 1535 41/106 (38.7%) vs Placebo 43/126 (34.1%) missed phase 3 result · pivotal pending
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04167462: The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5)
NCT03611751: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) (Week 16): BMS-986165 253/511 (49.5%) vs Placebo 22/255 (8.6%)
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Weak signal
NCT00111436: Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases.
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02203032: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001.
NCT02207244: Week 16 co-primary endpoints (VOYAGE 2, NCT02207244): IGA 0/1 84.1% guselkumab vs 8.5% placebo (p<0.001); PASI 90 70.0% guselkumab vs 2.4% placebo (p<0.001)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptorReliable signal
NCT02742441: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4%
NCT02368210: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 25.3% vs Vehicle Foam 3.9%
Halobetasol Propionate Lotion (Bryhali)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT02514577: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13%
NCT02515097: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 38.41% vs IDP-122 Vehicle Lotion 11.99%
Halobetasol Propionate / Tazarotene (Duobrii)ApprovedSmall moleculeGlucocorticoid receptor + retinoic acid receptorPartial signal
NCT02462122: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 2): 45.3% vs 12.5%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
NCT02462070: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 1): 35.8% vs 7.0%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
Icotrokinra (Icotyde)ApprovedPeptideIL-23 receptorReliable signal
NCT06095115: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7%
NCT06095102: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 56.7% vs Placebo 5.8%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01177800: PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001)
NCT00106847: Primary endpoint (PASI 75 at week 10), EXPRESS II trial -- official title fetched directly from the CT.gov API for this NCT matches word-for-word ('...Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Patients With Plaque-Type Psoriasis'): infliximab 3mg/kg 70%, 5mg/kg 75%, vs placebo 2% (P<0.001).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
NCT01474512: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) (Week 12): Ixe Q4W 76.4% | Ixe Q2W 81.8% vs Placebo 3.2%
Roflumilast (Zoryve Foam)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Partial signal
NCT04211389: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%)
NCT04211363: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 (Baseline (Day 1) and Week 8): Rofumilast Cream 0.3% 108/255 (42.4%) vs Vehicle Cream 8/132 (6.1%)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01358578: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%)
NCT01365455: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5%
Spesolimab (Spevigo)ApprovedMonoclonal antibodyIL-36 receptorReliable signal
NCT03782792: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT03956355: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) 35.4% (Standard Error 2.75) vs Vehicle Cream 6% (Standard Error 2.08)
NCT03983980: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) Cream Group 40.2% (Standard Error 2.82) vs Vehicle Cream Group 6.3% (Standard Error 1.99)
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT01722331: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8%
NCT01729754: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) (Week 12): Tildrakizumab 200 mg 65.6% | Tildrakizumab 100 mg 61.2% vs Placebo 5.8% | Etanercept 50 mg 48.2%
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT00307437: PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo.
NCT00267969: PASI 75 at week 12: ustekinumab 45mg 67.1% vs placebo 3.1% (difference 63.9%, 95% CI 57.8-70.1, p<0.0001); ustekinumab 90mg 66.4% vs placebo 3.1% (difference 63.3%, 95% CI 57.1-69.4, p<0.0001).
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40Reliable signalFeatured results are non-efficacy only in this race
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Amdokitug (Yisaituo)Phase 3Monoclonal antibodyIL-17Anot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Skilarence)Phase 3Small moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
EbdarokimabPhase 3Monoclonal antibodyIL-12/23 p40not yet gradedNo reviewed efficacy summary in this indication
EnvudeucitinibPhase 3Small moleculeTYK2Reliable signal
NCT06586112: PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all)
NCT06588738: ONWARD2, week 16 co-primary endpoints vs placebo (intention-to-treat, nonresponder imputation): PASI 75 70.4% with envudeucitinib 40 mg twice daily (n=433) vs 13.7% with placebo (n=211); sPGA 0/1 57.3% vs 5.7%; both P < 0.0001 (Cochran-Mantel-Haenszel). PASI 90: 53.1% vs 4.3%. Apremilast 30 mg twice daily (n=215): PASI 75 38.6%, sPGA 0/1 27.4% (Alumis AAD 2026 late-breaking presentation).
FadeucravacitinibPhase 3Small moleculeTYK2Partial signal
NCT06109818: PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved
GumokimabPhase 3Monoclonal antibodyIL-17APartial signal
NCT06066125: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7%
HB0017Phase 3Monoclonal antibodyIL-17APartial signal
NCT05531682: Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens.
HS-10374Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-20137Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
ImsidolimabPhase 3Monoclonal antibodyIL-36 receptorPartial signalFeatured results are non-efficacy only in this race
LecankitugPhase 3Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4Partial signal
NCT04839328: PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%)
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03390101: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%)
Nomelcitinib (D-2570)Phase 3Small moleculeTYK2Partial signal
NCT06278350: Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001)
PicankibartPhase 3Monoclonal antibodyIL-23 p19Reliable signal
NCT06049810: PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons
NCT05645627: Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them.
PiclidenosonPhase 3Small moleculeAdenosine A3 receptorPartial signal
NCT03168256: PASI 75 at week 16: 9.7% (3mg) vs 2.6% (placebo), p=0.037; linear improvement through week 32 (PASI 75: 19.6%)
NCT01265667: PASI 75 at week 12: CF101 2 mg 8.5% vs placebo 6.9%, P=0.621, tested at a 0.035 significance level (J Drugs Dermatol 2016). missed
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
QL2106Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 3Small moleculeTYK2Partial signal
NCT06542614: At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks
VunakizumabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT04839016: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025).
NCT03463187: PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all
ZasocitinibPhase 3Small moleculeTYK2Reliable signal
NCT06973291: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib.
NCT06088043: Co-primary 1, sPGA 0/1 at week 16: 71.4% zasocitinib vs 10.7% placebo (p<0.001), met. Co-primary 2, PASI 75 at week 16 vs placebo: superiority shown per Takeda's topline release (response rates and p not printed in Takeda's releases), met. Ranked secondary, PASI 90 at week 16: 61.3% vs 5.0% placebo and 16.8% apremilast (p<0.001).
AvrukibartPhase 2Monoclonal antibodyIL-23 p19Partial signal
NCT07090330: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27).
SHR-1139Phase 2Monoclonal antibodyIL-23 p19, IL-36 receptorWeak signalNo reviewed efficacy summary in this indication
SonelokimabPhase 2Antibody-derived scaffoldIL-17A/FReliable signal
NCT03384745: Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo.
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 74 furthest-along competitors are listed; 45 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Skyrizi (risankizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
January 2027 (1)
Phase 1Healthy VolunteerRecruiting
Est. primary completion 2027-01 · NCT07466550 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-03 · NCT06063967 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-08 · NCT06880744 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Crohn's DiseaseNot yet recruiting
Est. primary completion 2027-12-31 · NCT07258641 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
February 2028 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2028-02 · NCT04524611 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3PsoriasisActive not recruiting
Est. primary completion 2028-04 · NCT04862286 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Crohn's DiseaseNot yet recruiting
Est. primary completion 2028-06-20 · NCT07177118 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2028-09 · NCT03398135 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-10-13 · NCT07872449 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2028-11-15 · NCT07499232 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2029-02 · NCT03105102 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2029-04 · NCT05995353 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Psoriatic ArthritisRecruiting
Est. primary completion 2029-08 · NCT06865105 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2030-01 · NCT06548542 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2031-10 · NCT07697456 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2034-07 · NCT07071519 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026ApprovalFDA approves SC induction regimen for Skyrizi in Crohn's disease
US, FDA · Source ↗